Lia M. Halasz

Dr. Lia M. Halasz

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2016 in Cancer
Verified
Journal Article
Open access
PDF file
LHLia M. Halasz
Lia M. Halasz
HUHajime Uno
Hajime Uno
MHMelissa Hughes
Melissa Hughes
TDThomas D'AMico
Thomas D'AMico
EDElisabeth U. Dexter
Elisabeth U. Dexter
RPRinaa S. Punglia
Rinaa S. Punglia
BACKGROUND: The optimal treatment for patients with brain metastases remains controversial as the use of stereotactic radiosurgery (SRS) alone, replacing whole‐brain radiation therapy (WBRT), has increased. This study determined the patterns of care at multiple institutions before 2010 and examined whether or not survival was different between patients treated with SRS and patients treated with WBRT.METHODS: This study examined the overall survival of patients treated with radiation therapy for brain metastases from non–small cell lung cancer (NSCLC; initially diagnosed in 2007‐2009) or breast cancer (initially diagnosed in 1997‐2009) at 5 centers. Propensity score analyses were performed to adjust for confounding factors such as the number of metastases, the extent of extracranial metastases, and the treatment center.RESULTS: Overall, 27.8% of 400 NSCLC patients and 13.4% of 387 breast cancer patients underwent SRS alone for the treatment of brain metastases. Few patients with more than 3 brain metastases or lesions ≥ 4 cm in size underwent SRS. Patients with fewer than 4 brain metastases less than 4 cm in size (n = 189 for NSCLC and n = 117 for breast cancer) who were treated with SRS had longer survival (adjusted hazard ratio [HR] for NSCLC, 0.58; 95% confidence Interval [CI], 0.38‐0.87; P = .01; adjusted HR for breast cancer, 0.54; 95% CI, 0.33‐0.91; P = .02) than those treated with WBRT.CONCLUSIONS: Patients treated for fewer than 4 brain metastases from NSCLC or breast cancer with SRS alone had longer survival than those treated with WBRT in this multi‐institutional, retrospective study, even after adjustments for the propensity to undergo SRS. Cancer 2016;122:2091–100. © 2016 American Cancer Society.

1 February 2013 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
LHLia M. Halasz
Lia M. Halasz
JWJane C. Weeks
Jane C. Weeks
BNBridget A. Neville
Bridget A. Neville
NTNathan Taback
Nathan Taback
RPRinaa S. Punglia
Rinaa S. Punglia

31 May 2022 in Practical Radiation Oncology
Verified
Journal Article
Closed access
LHLia M. Halasz
Lia M. Halasz
AAAlbert Attia
Albert Attia
LBLisa Bradfield
Lisa Bradfield
DBDaniel J. Brat
Daniel J. Brat
JKJohn P. Kirkpatrick
John P. Kirkpatrick
HSHelen A. Shih
Helen A. Shih

1 September 2020 in Advances in Radiation Oncology
Verified
Journal Article
Open access
ASAli M. Saeed
Ali M. Saeed
RKRahul Khairnar
Rahul Khairnar
ASAnkur M. Sharma
Ankur M. Sharma
GLGary L. Larson
Gary L. Larson
HTHenry K. Tsai
Henry K. Tsai
MMMark V. Mishra
Mark V. Mishra
As a means of limiting normal tissue toxicity, proton-beam therapy (PBT) is an emerging radiation modality for glioblastoma (GBM) reirradiation. However, data for recurrent GBM treated with PBT reirradiation is limited. Therefore, we analyzed treatment patterns, toxicities, and clinical outcomes of patients with recurrent GBM treated with PBT reirradiation using the multi-institutional Proton Collaborative Group registry. Prospectively collected data for patients with recurrent GBM who underwent PBT while enrolled in Proton Collaborative Group study 01-009 (NCT01255748) were analyzed. We evaluated overall survival (OS), progression-free survival (PFS), and toxicity. Toxicities were scored per the Common Terminology Criteria for Adverse Events, version 4.0. Descriptive statistics were used to report patient, tumor, and treatment characteristics. Multivariable analyses (MVA) for toxicity were conducted using logistic regression. The Kaplan-Meier method was used to calculate OS and PFS. MVA for OS and PFS was conducted using Cox proportional-hazards models. The SAS statistical software was used for the analysis. We identified 45 recurrent patients with GBM who underwent PBT reirradiation between 2012 and 2018. The median time between initial GBM diagnosis and recurrence was 20.2 months. The median follow-up time from PBT reirradiation was 10.7 months. Median PFS was 13.9 months (95% confidence interval [CI], 8.23-20.0 months) and median OS was 14.2 months (95% CI, 9.6-16.9 months) after PBT reirradiation. One patient experienced an acute grade 3 toxicity, 4 patients experienced late grade 3 toxicity (no grade ≥4 toxicities). MVA revealed that prior surgery was associated with a 91.3% decreased hazard of death (hazard ratio: 0.087; 95% CI, 0.02-0.42; P < .01). No explanatory variables were associated with PFS or grade 3 toxicities. This is the largest series to date reporting outcomes for PBT reirradiation of patients with recurrent GBM. Our analysis indicates that PBT is well tolerated and offers efficacy rates comparable with previously reported photon reirradiation.

1 January 2013 in Surgical Neurology International
Verified
Journal Article
Open access
JRJasonK Rockhill
JasonK Rockhill
LHLia M. Halasz
Lia M. Halasz
Stereotactic radiosurgery (SRS) and hypofractionated stereotactic radiotherapy (HFSRT) have become important treatment modalities for brain metastases. While effective, there are still areas of extensive debate on its appropriate use in patients with life-limiting diseases. This review provides an overview of the indications and challenges of SRS and HFSRT in the management of brain metastases.

1 July 2017 in Chinese Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SDSamuel E. Day
Samuel E. Day
LHLia M. Halasz
Lia M. Halasz
Maximal safe resection has long been the cornerstone of treatment for WHO grade I benign meningioma. However, as technology for both imaging and radiation delivery has advanced, radiation therapy has played an increasingly important role in the management of patients with WHO grade I meningioma. Radiation therapy, whether delivered as standard fractionated treatment over several weeks, stereotactic radiosurgery over 1 session, or multisession stereotactic radiation therapy, has been shown to provide excellent local control when used as an adjunct to surgery or as primary treatment. Here, we review the indications for radiation therapy for patients with WHO grade I meningioma, as well as the various techniques that have been developed. We also review the toxicities and late effects associated with treatment.